proxyvotesnow.com

Home › Companies › VERVE THERAPEUTICS INC. › 2023-2024

VERVE THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and VERVE THERAPEUTICS INC.’s Form 8-K, filed 2024-06-07 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 200Asset managers
  • 1,339Fund votes
  • 2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025

Explore VERVE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VERVE THERAPEUTICS INC.

These tallies are VERVE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-07 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VERVE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Burt Adelman, M.D. 27,760,743---- 17,141,07624,032,475 Majority: yes
Elect Director: Sekar Kathiresan, M.D. 44,455,131---- 448,06124,031,102 Majority: yes
Proposal 2: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal y 68,752,29276,802105,200 --0 Majority: yes
Proposal 3: Approval, on an Advisory Basis, of Compensation Paid to Company's Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to its named executive officers 39,396,0505,481,52425,644 --24,031,076 Majority: yes

Source: VERVE THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-07 — read the filing on EDGAR.

How asset managers voted at the VERVE THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 200 asset managers that disclosed a VERVE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VERVE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%
FOR: 39,396,050AGAINST: 5,481,524

VERVE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an Advisory Basis, of Compensation Paid to Company's Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to its named executive officers”): 39,396,050 for, 5,481,524 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 194 asset managers below cast 90% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 90%10%
FOR: 90.0%AGAINST: 10.0%ABSTAIN: 0.0%
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price6,892,9500 00For
BVF INC/IL6,500,0000 00For
ARK ETF Trust5,835,5300 00For
Vanguard5,797,9960 00For
Federated Hermes4,773,3420 00For
State Street4,337,2757,616 00For
BlackRock19,4382,456,626 00Against
Nikko Asset Management Americas, Inc.2,169,7140 00For
Novo Holdings A/S2,000,0000 00For
Redmile Group, LLC01,604,515 00Against
EcoR1 Capital, LLC1,250,0000 00For
Charles Schwab979,3780 00For
Nuveen880,9960 00For
JPMorgan860,0370 00For
TIAA824,4120 00For
MPM BioImpact LLC638,1630 00For
Palo Alto Investors LP575,5170 00For
Woodline Partners LP521,1570 00For
Fidelity487,37625,307 00For
Nikko Asset Management Co., Ltd.445,4780 00For
Northern Trust374,4311,989 00For
Goldman Sachs374,1600 00For
Cormorant Asset Management, LP350,0000 00For
Dimensional0292,890 00Against
Citadel291,0670 00For

Showing the 25 largest of 194 asset managers. See all 194 in the interactive database.

2. APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 57%1 YEAR 29%12%

The 183 asset managers below cast 99.9% of the shares they voted on this item FOR (34,437 for, 30 against).

FOR: 34,437 (0.1%)AGAINST: 30 (0.0%)ONE YEAR: 30,057,085 (56.6%)1 YEAR: 15,583,351 (29.4%)1-YR: 6,500,000 (12.2%)1YR: 575,517 (1.1%)THREE YEARS: 294,566 (0.6%)3 YEARS: 27,443 (0.1%)2 YEARS: 1,000 (0.0%)UNKNOWN: 540 (0.0%)
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO OUR NAME” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price00 00One Year
BVF INC/IL00 001-Yr
ARK ETF Trust00 001 Year
Vanguard00 00One Year
Federated Hermes00 001 Year
State Street00 00One Year
BlackRock00 00One Year
Nikko Asset Management Americas, Inc.00 00One Year
Novo Holdings A/S00 00One Year
Redmile Group, LLC00 001 Year
Charles Schwab00 001 Year
Nuveen00 00One Year
TIAA00 00One Year
MPM BioImpact LLC00 001 Year
Palo Alto Investors LP00 001Yr
Woodline Partners LP00 00One Year
Fidelity00 00One Year
Nikko Asset Management Co., Ltd.00 00One Year
Northern Trust00 001 Year
Goldman Sachs00 00One Year
Cormorant Asset Management, LP00 001 Year
Dimensional00 00Three Years
Citadel00 00One Year
JPMorgan1,5000 001 Year
Direxion Shares ETF Trust00 00One Year

Showing the 25 largest of 183 asset managers. See all 183 in the interactive database.

3. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 68,752,292AGAINST: 76,802

VERVE THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered”): 68,752,292 for, 76,802 against, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 55 asset managers below cast 100% of the shares they voted on this item FOR (22,866,508 for, 0 against).

FOR 100%
FOR: 22,866,508 (100.0%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust5,835,5300 00For
Vanguard5,734,1440 00For
T. Rowe Price2,576,8960 00For
Federated Hermes2,386,6710 00For
State Street1,630,6070 00For
BlackRock1,007,9220 00For
TIAA824,4120 00For
Charles Schwab489,6890 00For
Goldman Sachs271,0880 00For
Dimensional263,9800 00For
Direxion Shares ETF Trust244,0440 00For
JPMorgan194,5500 00For
Fidelity191,2150 00For
AIG/SunAmerica127,4700 00For
AMERICAN BEACON FUNDS98,0510 00For
Global X93,5250 00For
Equitable83,5200 00For
ProShares80,3710 00For
American Century80,3560 00For
Columbia Threadneedle74,0200 00For
Lincoln Financial70,6240 00For
Northwestern Mutual70,4530 00For
Northern Trust51,9590 00For
Nushares ETF Trust51,4690 00For
TARGET PORTFOLIO TRUST44,6000 00For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

4. Election of two Class III directors to our board of directors, each to serve until the 2027 annual meeting of stockholders: Burt Adelman, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%WITHHELD 38%
FOR: 27,760,743WITHHELD: 17,141,076

VERVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Burt Adelman, M.D.”): 27,760,743 for, 17,141,076 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 54 asset managers below cast 100% of the shares they voted on this item FOR (17,213,253 for, 0 against).

FOR 75%ABSTAIN 25%
FOR: 17,213,253 (75.4%)ABSTAIN: 5,618,771 (24.6%)
Largest asset managers voting on “Election of two Class III directors to our board of directors, each to serve until the 2027 annual meeting of ” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust5,835,5300 00For
Vanguard5,734,1440 00For
T. Rowe Price2,576,8960 00For
Federated Hermes2,386,6710 00For
State Street17,0880 1,613,5190Abstain
BlackRock00 1,007,9220Abstain
TIAA00 824,4120Abstain
Charles Schwab00 489,6890Abstain
Goldman Sachs00 271,0880Abstain
Dimensional00 263,9800Abstain
Direxion Shares ETF Trust00 244,0440Abstain
JPMorgan194,5500 00For
Fidelity165,9080 25,3070For
AIG/SunAmerica00 127,4700Abstain
AMERICAN BEACON FUNDS98,0510 00For
Global X00 93,5250Abstain
Equitable00 83,5200Abstain
ProShares00 80,3710Abstain
American Century00 80,3560Abstain
Columbia Threadneedle00 74,0200Abstain
Lincoln Financial00 70,6240Abstain
Northwestern Mutual70,4530 00For
Northern Trust00 51,9590Abstain
Nushares ETF Trust00 51,4690Abstain
TARGET PORTFOLIO TRUST44,6000 00For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

5. Election of two Class III directors to our board of directors, each to serve until the 2027 annual meeting of stockholders: Sekar Kathiresan, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 44,455,131WITHHELD: 448,061

VERVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sekar Kathiresan, M.D.”): 44,455,131 for, 448,061 withheld, per its Form 8-K filed 2024-06-07 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 54 asset managers below cast 100% of the shares they voted on this item FOR (22,563,249 for, 0 against).

FOR 99%
FOR: 22,563,249 (98.8%)ABSTAIN: 268,775 (1.2%)
Largest asset managers voting on “Election of two Class III directors to our board of directors, each to serve until the 2027 annual meeting of ” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARK ETF Trust5,835,5300 00For
Vanguard5,734,1440 00For
T. Rowe Price2,576,8960 00For
Federated Hermes2,386,6710 00For
State Street1,628,8340 1,7730For
BlackRock1,007,9220 00For
TIAA824,4120 00For
Charles Schwab489,6890 00For
Goldman Sachs271,0880 00For
Dimensional00 263,9800Abstain
Direxion Shares ETF Trust244,0440 00For
JPMorgan194,5500 00For
Fidelity191,2150 00For
AIG/SunAmerica127,4700 00For
AMERICAN BEACON FUNDS98,0510 00For
Global X93,5250 00For
Equitable83,5200 00For
ProShares80,3710 00For
American Century80,3560 00For
Columbia Threadneedle74,0200 00For
Lincoln Financial68,9480 1,6760For
Northwestern Mutual70,4530 00For
Northern Trust51,9590 00For
Nushares ETF Trust51,4690 00For
TARGET PORTFOLIO TRUST44,6000 00For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

ONE YEAR 99.8%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (766 for, 0 against).

FOR: 766 (0.1%)ONE YEAR: 610,438 (99.9%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at VERVE THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JPMorgan00 00One Year
Desjardins Global Asset Management Inc.00 00One Year
BEACON INVESTMENT ADVISORY SERVICES, INC.7660 00For

Largest VERVE THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of VERVE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting.

Top VERVE THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager Shares voted
1T. Rowe Price 6,892,950
2BVF INC/IL 6,500,000
3ARK ETF Trust 5,835,530
4Vanguard 5,797,996
5Federated Hermes 4,773,342
6State Street 4,344,891
7BlackRock 2,476,064
8Nikko Asset Management Americas, Inc. 2,169,714
9Novo Holdings A/S 2,000,000
10Redmile Group, LLC 1,604,515

Shown as share counts, not percentages: no shares-outstanding figure has been matched to VERVE THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VERVE THERAPEUTICS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 200 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,339 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VERVE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-07.

VERVE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.